ArticleThe Lancet. Child & adolescent health2023

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.

Eric A F Simões et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.